STING1 and neoplasm: Defined innate immune mechanisms reveal that STING agonists possess great power in antiviral processes, and antitumor immune responses are mainly attributed to the secretion of type I IFN and a broad chemokine profile, such as CXCL10 and IL6, which facilitate the recruitment and activation of natural killer (NK) cells and T cells in the tumor microenvironment [18,19,20].